{
  "drug_name": "sage",
  "nbk_id": "NBK617061",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK617061/",
  "scraped_at": "2026-01-11T18:47:52",
  "sections": {
    "indications": "Familial atypical multiple mole melanoma (FAMMM) syndrome is a rare hereditary disorder characterized by the presence of numerous clinically atypical nevi, often more than 50, and a significantly increased lifetime risk of melanoma. First described in 1820 by William Norris as a “fungoid disease,” FAMMM, also known as dysplastic nevus syndrome, presents substantial challenges in diagnosis and management due to its phenotypic variability and unpredictable clinical course.\n[1]\n\nFAMMM syndrome results from inherited mutations in tumor suppressor genes associated with melanoma susceptibility, most notably CDKN2A, CDK4, and ARF.\n[2]\n[3]\nThis genetic predisposition confers a markedly elevated risk of melanoma development compared to the general population. About 5-10% of cutaneous melanomas occur due to hereditary predisposition; of these patients, approximately 20% to 40% have CDKN2A mutations.\n[1]\n\nAtypical nevi associated with FAMMM typically exhibit irregular borders, variations in color, and larger size compared to common nevi. These nevi may appear anywhere on the body, but they often manifest on sun-exposed areas such as the back, chest, and limbs. Histologically, these nevi display dysplastic features, including architectural disarray and cytological abnormalities, underscoring their potential for malignant transformation.\n\nA lifelong propensity for the development of melanoma characterizes the natural history of FAMMM syndrome. Individuals affected by this syndrome often experience the emergence of numerous atypical nevi during childhood or adolescence, with the risk of melanoma diagnosis increasing with age. The development of up to 50 primary melanomas has been reported in patients with FAMMM syndrome.\n[4]\nDespite heightened surveillance and preventive measures, melanomas arising in the context of FAMMM may exhibit aggressive behavior, contributing to increased morbidity and mortality rates. In addition to melanoma, these patients have an increased risk of developing pancreatic carcinomas as well as other internal malignancies.\n[5]\n[6]",
    "mechanism": "The etiology of FAMMM is multifactorial, involving a combination of genetic predisposition and environmental influences. One of the primary causes of FAMMM syndrome is the inheritance of germline mutations in genes associated with melanoma susceptibility. The most commonly implicated genes include\nCDKN2A\nand\nCDK4\n, although mutations in other genes, such as MITF and TERT, have also been linked to familial melanoma syndromes.\n[2]\nThe\nCDKN2A\ngene is located on locus 9p21 and encodes for p16INK4a and p14ARF proteins.\n[7]\nThese mutations disrupt the normal regulation of cell growth and proliferation via the cell cycle, leading to an increased risk of melanocyte transformation and the development of melanoma.\n[8]\nINK4a\nmutations can also be associated with head and neck squamous cell carcinoma.\n[9]\nThe inheritance pattern of FAMMM syndrome is typically autosomal dominant, with affected individuals inheriting a mutated copy of the relevant gene from one parent.\n[4]\n\nWhile genetic factors play a significant role in predisposing individuals to FAMMM syndrome, environmental exposures also contribute to disease development. Ultraviolet (UV) radiation from sunlight is a well-established environmental risk factor for melanoma, and individuals with FAMMM syndrome may exhibit increased susceptibility to the carcinogenic effects of UV radiation.\n[10]\nProlonged sun exposure, particularly during childhood and adolescence, can exacerbate the risk of melanoma development in individuals with FAMMM syndrome. Other environmental factors, such as exposure to ionizing radiation and certain chemicals, may also influence disease risk, although their contribution to FAMMM pathogenesis requires further investigation.\n[11]\n[12]\n[13]\n\nThe interplay between genetic susceptibility and environmental exposures is thought to play a crucial role in the development of FAMMM syndrome.\n[14]\n[15]\nIndividuals with germline mutations in melanoma susceptibility genes may exhibit heightened sensitivity to environmental carcinogens, increasing their susceptibility to melanoma development. Conversely, environmental factors, such as UV radiation exposure, may influence the penetrance and expressivity of disease-associated mutations, modulating the clinical phenotype of FAMMM syndrome. Elucidating the complex interactions between genetic and environmental factors is essential for comprehensively understanding FAMMM pathogenesis and developing targeted preventive strategies.",
    "monitoring": "A thorough dermatologic evaluation is essential for identifying suspicious lesions and assessing disease burden in individuals with FAMMM syndrome. Initial evaluation should also include a thorough personal/family history, including screening for melanoma and pancreatic cancer among first, second, and third-degree relatives.\n[3]\nDermoscopy may aid in the identification of suspicious features associated with melanoma. Atypical nevi should be evaluated via the ABCDE \"Asymmetry, Border, Color, Diameter, Evolution) characteristics. Total body photography and sequential digital dermoscopy imaging may also be utilized for longitudinal monitoring of nevi and early detection of changes suggestive of malignant transformation.\n\nGenetic testing for mutations in melanoma susceptibility genes, such as CDKN2A and CDK4, may be indicated in individuals with a strong family history of melanoma or multiple atypical nevi. Identification of pathogenic mutations can facilitate risk stratification, genetic counseling, and targeted surveillance strategies for affected individuals and their family members. In recent years, two statistical models have emerged to help identify CDKN2A-mutation-bearing individuals; these include MELPREDICT and MelaPRO.\n[17]\nThese models estimate the likelihood of mutation carriage for any given individual or family member based on cancer patterns observed within the family. Despite these available tools, the use of genetic testing for screening remains controversial.\n[6]\n\nHistopathologic examination of suspicious lesions through biopsy is essential for confirming the diagnosis of melanoma and assessing the degree of dysplasia in atypical nevi. The histologic characteristics of melanoma in FAMMM patients do not differ significantly from those in sporadic melanoma cases.\n[6]\n\nImaging studies such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) may be utilized for staging and surveillance of melanoma, particularly in cases of suspected metastatic disease.\n[21]\nLymph node mapping with sentinel lymph node biopsy may also be performed to evaluate regional lymph node involvement in individuals with clinically localized melanoma.\n[22]\n\nRegular follow-up and surveillance are crucial components of the evaluation process for individuals with FAMMM syndrome. Surveillance protocols typically include periodic skin examinations every 6 to 12 months, dermatologic photography, and imaging studies tailored to individual risk factors and disease stage. While established diagnostic guidelines for FAMMM syndrome are lacking, recommendations for surveillance and management are outlined by expert consensus guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) and the American Academy of Dermatology (AAD).\n[21]\nThese guidelines emphasize the importance of early detection, risk stratification, and multidisciplinary management of individuals at increased risk of melanoma due to FAMMM syndrome.",
    "administration": "FAMMM syndrome necessitates a multifaceted management approach aimed at mitigating the risk of melanoma development, detecting cutaneous malignancies early, and optimizing patient outcomes. Treatment strategies encompass a combination of surgical, medical, and preventive interventions, guided by established clinical guidelines and expert consensus recommendations.\n[17]\n[23]\n\nSurgical management plays a central role in the treatment of FAMMM, with excision remaining the cornerstone for both melanoma and atypical nevi. Suspicious lesions undergo surgical excision with appropriate margins to ensure complete removal and minimize the risk of recurrence. Additionally, sentinel lymph node biopsy may be indicated for individuals with clinically localized melanoma to assess regional lymph node involvement and guide further management decisions. In cases of confirmed lymph node metastases, lymphadenectomy may be performed, while wide local excision addresses recurrent or advanced melanoma lesions.\n[21]\n[22]\n\nMedical management encompasses adjuvant therapy options tailored to individuals with high-risk melanoma features. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, as well as targeted therapies directed against specific molecular aberrations like BRAF inhibitors, have demonstrated efficacy in improving outcomes for patients with advanced melanoma. Systemic surveillance with regular imaging studies may also be recommended for individuals at high risk of melanoma recurrence or metastasis, particularly those with a history of advanced-stage disease or genetic predisposition to melanoma.\n[23]\n[24]\n[25]\n\nPreventive measures are paramount in FAMMM management, focusing on sun protection, regular surveillance, and genetic counseling. Sun protection measures, including sunscreen use, protective clothing, and sun avoidance during peak hours, are essential for reducing the risk of melanoma development. Regular skin self-examinations and dermatologic surveillance facilitate the early detection of new or changing lesions, enabling prompt evaluation and intervention. Genetic counseling plays a crucial role in educating affected individuals and their families about familial risk factors, inheritance patterns, and the importance of informed decision-making.\n[17]\n[21]\n\nEstablished guidelines for melanoma management, such as those from the NCCN and the AAD, provide evidence-based recommendations for treatment and surveillance strategies in individuals with FAMMM syndrome. Multidisciplinary collaboration among dermatologists, oncologists, genetic counselors, and other healthcare providers is essential for delivering comprehensive care and optimizing outcomes in patients with FAMMM syndrome. This integrated approach addresses the complex needs of individuals with FAMMM, emphasizing prevention, early detection, and personalized treatment strategies to mitigate the impact of this hereditary disorder.",
    "adverse_effects": "FAMMM syndrome presents various complications primarily arising from the heightened risk of melanoma development and the potential for aggressive disease behavior. Chief among these complications is the increased likelihood of melanoma, significantly elevating the lifetime risk compared to the general population. Melanomas associated with FAMMM may exhibit aggressive features, including rapid growth, deep invasion, lymphatic and hematogenous spread, and resistance to treatment. In FAMMM patients, melanocytic nevi harboring cells with CDKN2A loss of heterozygosity may be at increased risk of developing melanoma.\n[2]\n\nMoreover, melanomas in individuals with FAMMM syndrome have an augmented propensity for metastasis to regional lymph nodes and distant organs, leading to advanced-stage disease and poorer prognosis. Metastatic melanoma is associated with significant morbidity and mortality, often necessitating aggressive treatment modalities such as systemic therapy, immunotherapy, and targeted therapy.\n\nDespite appropriate treatment, melanomas in individuals with FAMMM syndrome may recur locally or metastasize to distant sites following initial management, posing challenges in terms of treatment options and prognosis. Recurrent melanoma requires close surveillance and multidisciplinary management strategies.\n\nBeyond the physical manifestations, the diagnosis of FAMMM syndrome and the heightened risk of melanoma can have a profound psychological impact on affected individuals and their families. Fear of disease recurrence, anxiety about surveillance procedures, and concerns about familial inheritance may contribute to psychological distress and reduced quality of life.\n\nWhile melanoma is the primary concern in FAMMM syndrome, affected individuals may also be at an increased risk of developing other malignancies, including non-melanoma skin cancers and internal malignancies.\n[26]\nMutations in one CDKN2A variant, known as the p16-Leiden variant, may lead to an increased risk of developing pancreatic and esophageal cancer.\n[7]\n[27]\n[28]\nThe association between FAMMM and pancreatic cancer was first described in 1991 by Lynch and Fusaro.\n[29]\nRegular surveillance for secondary malignancies is essential for early detection and timely intervention."
  }
}